NEW YORK, June 13, 2017 /PRNewswire/ --
DailyStockTracker.com has issued research reports on Amgen Inc.
(NASDAQ: AMGN), Pulmatrix Inc. (NASDAQ: PULM), Argos Therapeutics
Inc. (NASDAQ: ARGS), and Bioverativ Inc. (NASDAQ: BIVV). According
to an article on Seeking Alpha, the high-beta Biotech sector has
been subdued since it opened the year with a solid January. The
dearth of M&A activity since then has been a primary
contributor to the very narrow range this part of the markets have
been gyrating within throughout most of 2017. Earnings have been
solid from the industry, but not spectacular. Learn more about
these stocks by downloading their comprehensive and free reports
from DailyStockTracker.com member's area at:
http://dailystocktracker.com/register/
Amgen
On Monday, shares in Thousand Oaks,
California headquartered Amgen Inc. rose 0.50%, ending the
day at $164.88. The stock recorded a
trading volume of 4.34 million shares, which was above its three
months average volume of 3.71 million shares. The Company's shares
have advanced 3.00% in the last one month and 12.77% since the
start of this year. The stock is trading above its 50-day and
200-day moving averages by 2.51% and 2.68%, respectively. Moreover,
shares of Amgen, which discovers, develops, manufactures, and
delivers human therapeutics worldwide, have a Relative Strength
Index (RSI) of 66.22.
On June 08th, 2017,
Amgen announced that it will present at the Goldman Sachs
38th Annual Global Healthcare Conference on June 13th, 2017, at 2:40 p.m. PT in Rancho
Palos Verdes, Calif. Sean E.
Harper, M.D., executive vice president of Research and
Development, will present at the conference. The live audio of the
presentation can be accessed under Investors section of the
Company's website. AMGN complete research report is just a click
away and free at:
http://dailystocktracker.com/registration/?symbol=AMGN
Pulmatrix
Shares in Lexington,
Massachusetts headquartered Pulmatrix Inc. ended the day
4.18% lower at $2.52 with a total
trading volume of 182,697 shares. The stock has surged 327.12% on
an YTD basis. The Company's shares are trading above their 200-day
moving average by 18.96%. Furthermore, shares of Pulmatrix, which
engages in developing inhaled therapies to address serious
pulmonary diseases using its inhaled Small Particles Easily
Respirable and Emitted technology, have an RSI of 40.55. The
complimentary report on PULM can be downloaded at:
http://dailystocktracker.com/registration/?symbol=PULM
Argos Therapeutics
At the close of trading on Monday, shares in Durham, North Carolina headquartered Argos
Therapeutics Inc. finished 1.05% lower at $0.40 with a total trading volume of 121,759
shares. The stock is trading below its 50-day moving average by
7.04%. Shares of the Company, which focuses on the development and
commercialization of personalized immunotherapies for the treatment
of cancer and infectious diseases, have an RSI of 47.32. Sign up
for your complimentary research report on ARGS at:
http://dailystocktracker.com/registration/?symbol=ARGS
Bioverativ
Waltham, Massachusetts
headquartered Bioverativ Inc.'s shares recorded a trading volume of
1.05 million shares at the end of yesterday's session. The stock
closed the day 3.05% lower at $55.24.
The Company's shares have advanced 0.36% in the past month, 5.99%
in the previous three months, and 16.29% on an YTD basis. The stock
is trading above its 200-day moving average by 6.75%. Additionally,
shares of Bioverativ, which focuses on the research, discovery,
development, and commercialization of therapies for the treatment
of hemophilia and other blood disorders in the US and Japan, have an RSI of 46.45.
On May 23rd, 2017,
Bioverativ announced that it has entered into a definitive
agreement to acquire South San
Francisco-based True North Therapeutics, a privately held,
clinical-stage, rare disease biotechnology company, for an upfront
payment of $400 million plus assumed
cash. True North investors are also eligible to receive additional
payments of up to $425 million
contingent on the achievement of future development, regulatory and
sales milestones.
On May 24th, 2017,
research firm Credit Suisse upgraded the Company's stock rating
from 'Underperform' to 'Neutral'. Get free access to your research
report on BIVV at:
http://dailystocktracker.com/registration/?symbol=BIVV
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA